Eye on ESMO: Day 1 – Access in spotlight before data deluge
Europe’s biggest cancer conference ESMO is underway
Europe’s biggest cancer conference ESMO is underway
BMS and Nektar’s combination latest in frenzied immunotherapy field
Merck steals a march on rival BMS.
BMS hopes combinations will maintain Opdivo lead after setback
Analysts expect Opdivo to recover via combination trials
Regulators reviewing use in head and neck cancer.
NICE said survival benefits are unclear.